+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 26 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a drug called brenipatide when added to standard treatment for adults with major depressive disorder. The study compares brenipatide plus standard care to a placebo plus standard care to see if it can delay the return of major depressive symptoms. This is a phase 3, randomized, double-blind trial sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all given by subcutaneous injection along with their standard care. The study has four periods a screening phase lasting about one month, a combined treatment and post-treatment phase lasting at least 12 months, and a safety follow-up period of about two months. The total participation time may vary and can be shortened if symptoms worsen or if participants withdraw. During the study, participants will self-inject the study medication and keep electronic and paper diaries, complete questionnaires, and attend scheduled visits. Researchers will measure the time to relapse of major depressive disorder symptoms as the main outcome. Other assessments include changes in body weight, depression severity, functional impairment, anxiety levels, quality of life, and presence of treatment-related antibodies. Safety monitoring will continue throughout the study and follow-up periods.

Age: 18Years - 75YearsAll GendersPhase 3
170 locations
R

Actively Recruiting

This trial is focused on adults aged 50 and older with mild to moderate Alzheimers disease. Researchers aim to evaluate the safety and tolerability of Zunveyl, a medication taken orally, during 12 weeks of routine use. The study also looks at how the drug affects neuropsychiatric symptoms and caregiver distress for these patients. Participants will take Zunveyl delayed-release tablets twice daily, starting with 5 mg from Weeks 1 to 4, then increasing to 10 mg twice daily from Weeks 5 to 12. This open-label, phase 4 study monitors participants throughout this 12-week treatment period to assess how well they tolerate the medication and to observe any side effects. During the study, participants and their caregivers will attend regular visits where assessments will be made including safety checks, neuropsychiatric evaluations using the Neuropsychiatric Inventory NPI-12, and measurements of caregiver distress. Researchers will track adverse events, treatment interruptions, dose reductions, and overall tolerability scores up to Week 17. The total participation lasts about 12 weeks with follow-up assessments to evaluate ongoing safety and effects.

Age: 50Years +All GendersPhase 4
22 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the immune response and safety of an investigational combined measles, mumps, rubella, and varicella vaccine MMRVNS compared to the already licensed MMRV vaccine ProQuad. The study focuses on healthy children aged 15 months to 6 years who have previously received a first dose of any measles, mumps, rubella, and varicella-containing vaccine. This Phase 3a, randomized, observer-blind trial aims to assess prevention by comparing these two vaccines when given as a second dose intramuscularly. Participants receive a single intramuscular dose of either the investigational MMRVNS vaccine or the licensed MMRV vaccine on Day 1. The study uses a parallel design with two groups one receiving MMRVNS and the other receiving MMRV. The vaccines are administered as a second dose to children previously vaccinated according to their countrys immunization schedule. The study monitors participants closely for immune response and safety after vaccination. Throughout the study, children undergo assessments including blood tests to measure Immunoglobulin G IgG responses against measles, mumps, rubella, and varicella at Day 43. Safety evaluations include monitoring for injection site reactions, systemic events, and adverse events up to 181 days after vaccination. The study tracks solicited and unsolicited adverse events and serious adverse events to understand the safety profile. Participation lasts until study completion, with multiple follow-up periods to ensure thorough monitoring.

Age: 15Months - 6YearsAll GendersPhase 3
17 locations
E

Actively Recruiting

Researchers are evaluating the drug TNX-102 SL to see if it helps treat adults with moderate to severe major depressive disorder MDD. This study aims to compare TNX-102 SL with a placebo to determine its effect on depression symptoms using a rating scale, and to assess the safety and medical issues participants may experience while taking the drug. Participants will take either 5.6 mg of TNX-102 SL two 2.8 mg tablets or matching placebo tablets every night at bedtime for six weeks. During the study, participants will visit the clinic every two weeks for checkups and tests to monitor their progress. Throughout the study, researchers will assess changes in depression severity using the MADRS score and other measures such as sleep disturbance and clinical impression scales. Safety and tolerability will also be monitored. Participation involves regular clinic visits over the six-week treatment period, with assessments occurring at baseline and every two weeks until the study concludes.

Age: 18Years +All GendersPhase 2
27 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of a new multivalent pneumococcal vaccine called PG4 in healthy infants. This vaccine is being compared to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC. The study aims to see how well the new vaccine helps fight germs that cause pneumonia, meningitis, and ear infections, and whether it provides additional protection against pneumococcal disease compared to the existing vaccine. The study includes three groups of infants based on age and location. Group 1 involves about 3000 infants who are 2 months old and will receive either PG4 or 20vPnC shots into the left thigh muscle at 2, 4, 6, and 12 to 15 months of age. Groups 2 and 3, with smaller numbers of infants from outside the United States aged 2 to 6 months, will receive different schedules of PG4 or 20vPnC either intramuscularly or under the skin. Each infant will be randomly assigned to one of the vaccine types and administration methods. Participants will be involved in the study for about 12 to 19 months depending on their group. During this time, infants will attend six clinic visits and one phone call, where parents or guardians will be asked about any side effects experienced. Blood samples will be collected three times to measure the immune response through proteins that fight the pneumococcal disease germs. The study also monitors local and systemic reactions, adverse events, and serious adverse events following vaccination.

Age: 42Days - 211DaysAll GendersPhase 3
130 locations
P

Actively Recruiting

Researchers are evaluating a new brain stimulation treatment called accelerated transcranial magnetic stimulation TMS for adults aged 18 to 65 with post-traumatic stress disorder PTSD. PTSD causes symptoms like flashbacks, avoidance, mood changes, and heightened alertness after trauma. This pilot study focuses on using brain scans to guide personalized TMS targeting the brain areas involved in fear and control to improve symptoms. The study aims to assess if this fast-paced treatment is practical, safe, and shows early signs of reducing PTSD symptoms. Participants first undergo a brain scan fMRI to map connections between their right amygdala fear center and right dorsolateral prefrontal cortex control area. Using this map, they receive accelerated continuous theta burst stimulation cTBS to the identified brain target. Treatment lasts 5 consecutive days with 10 short sessions each day, totaling 90,000 magnetic pulses. The procedure uses a neuronavigation system for precise coil placement and is monitored continuously for safety. During the study, participants have a screening and baseline phase, followed by the 5-day treatment and then a 3-month follow-up period. Researchers assess PTSD symptoms using questionnaires and interviews at baseline, after treatment, and at 1 and 3 months. Repeat brain scans evaluate changes in brain connectivity. Safety is closely monitored throughout, including side effects like headaches. Total participation lasts about 3.5 months.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
1 location
A

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a method of cervical ripening using a Foley catheter for women who are having their first baby and are scheduled for labor induction at term 37 weeks or more. The study compares outpatient cervical ripening with a Foley catheter to the usual inpatient cervical ripening methods. The aim is to see if outpatient use of the Foley catheter reduces the rate of Cesarean delivery and lowers risks for mothers and newborns compared to inpatient care. Participants will be randomly assigned to one of two groups one group will begin cervical ripening with a Foley balloon catheter at home outpatient, while the other group will start cervical ripening in the hospital using either a Foley balloon or another cervical ripening method. The trial focuses on comparing these approaches to find the best care process for labor induction. During the study, researchers will monitor Cesarean delivery rates at delivery as the primary outcome. They will also assess maternal and neonatal health up to 6 weeks after delivery, including maternal satisfaction, perceived control during birth, length of hospital stay, and neonatal intensive care admissions. Participants will be followed closely with various assessments and questionnaires to measure these outcomes and ensure safety throughout the postpartum period.

Age: 18Years - 60YearsFEMALEPhase Not Applicable
6 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness of combination antibiotic therapy compared to single antibiotic therapy for adults hospitalized with Staphylococcus aureus bloodstream infections. This study focuses on patients identified as high-risk early in their infection and aims to determine if combination therapy improves outcomes compared to monotherapy. Both methicillin-sensitive and methicillin-resistant bacterial infections are included. The trial is a randomized, crossover Phase 4 study conducted in hospitals. Participants with methicillin-sensitive Staphylococcus aureus bacteremia MSSAB will receive either a single intravenous beta-lactam antibiotic cefazolin or nafcillin or combination therapy including that beta-lactam plus ertapenem. Those with methicillin-resistant Staphylococcus aureus bacteremia MRSAB will be treated with either monotherapy of vancomycin or daptomycin or combination therapy with daptomycin plus ceftaroline. Treatment assignments alternate monthly by hospital. Low-risk patients receive usual care without randomization. During the study, participants will be monitored from enrollment through 30 and 90 days for various outcomes including a desirability of outcome ranking, hospital-free days alive, mortality rates, bacteremia-free days, hospital length of stay, direct hospital costs, antibiotic costs, antibiotic-associated adverse events, and Clostridioides difficile infections. Data from all hospitalized patients with SAB at participating hospitals will be analyzed. The study is expected to complete in January 2029.

Age: 18Years +All GendersPhase 4
13 locations
P

Actively Recruiting

Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.

Age: 50Years - 70YearsAll GendersPhase 3
832 locations

1-10 of 26

1